CA2640663A1 - Intranasal delivery system - Google Patents
Intranasal delivery system Download PDFInfo
- Publication number
- CA2640663A1 CA2640663A1 CA002640663A CA2640663A CA2640663A1 CA 2640663 A1 CA2640663 A1 CA 2640663A1 CA 002640663 A CA002640663 A CA 002640663A CA 2640663 A CA2640663 A CA 2640663A CA 2640663 A1 CA2640663 A1 CA 2640663A1
- Authority
- CA
- Canada
- Prior art keywords
- delivery device
- dose
- intranasal
- intranasal delivery
- probe
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0065—Inhalators with dosage or measuring devices
- A61M15/0068—Indicating or counting the number of dispensed doses or of remaining doses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0065—Inhalators with dosage or measuring devices
- A61M15/0068—Indicating or counting the number of dispensed doses or of remaining doses
- A61M15/0081—Locking means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/07—General characteristics of the apparatus having air pumping means
- A61M2205/071—General characteristics of the apparatus having air pumping means hand operated
- A61M2205/073—Syringe, piston type
Abstract
A kit for intranasal delivery, comprises a dose, a diluent in which the dose may be combined, and an intranasal device. The intranasal device comprises an intranasal probe having a dose delivery aperture and a dose administrator having a first end and a second end, wherein the first end is responsive to the intranasal probe. An intranasal probe coupler is responsive to the intranasal probe and the first end of the dose administrator, wherein the intranasal probe coupler has at least one aperture which communicates between the dose administrator and the intranasal probe.
Claims (34)
1. An intranasal dose delivery device, comprising:
a. a stream delivery element;
b. a dose delivery aperture element coupled to said stream delivery element;
c. an intranasal probe responsive to said dose delivery aperture;
d. a flexible dose administrator coupled to said intranasal probe; and e. a force application element coupler having a first end coupled to said flexible dose administrator and a second end configured to couple to a force application element.
a. a stream delivery element;
b. a dose delivery aperture element coupled to said stream delivery element;
c. an intranasal probe responsive to said dose delivery aperture;
d. a flexible dose administrator coupled to said intranasal probe; and e. a force application element coupler having a first end coupled to said flexible dose administrator and a second end configured to couple to a force application element.
2. An intranasal delivery device according to claim 1, wherein said stream delivery element has an aperture having a diameter of about 0.75 millimeters (about 0.030 inches).
3. An intranasal delivery device according to claim 2, wherein said flexible dose administrator has a cylindrical exterior surface.
4. An intranasal delivery device according to claim 3, wherein said cylindrical exterior surface has a diameter of about 6 millimeters (about 0.250 inches).
5. An intranasal delivery device according to claim 4, wherein said cylindrical exterior surface has a length of about 150 millimeters (about 5.9 inches).
6. An intranasal delivery device according to claim 5, further comprising a force dissemination contact surface having hebetated termini coupled to said intranasal probe.
7. An intranasal delivery device according to claim 6, wherein said force dissemination contact surface responsive to said flexible intranasal probe comprises a sphere cap, wherein said sphere cap and said cylindrical exterior surface of said flexible dose administrator form a contiguous surface.
8. An intranasal delivery device according to claim 7, wherein said sphere cap has a radius of about 3 millimeters (about 0.125 inches) and a sphere cap height of about 1 millimeters (about 0.040 inches).
9. An intranasal delivery device according to claim 8, wherein said intranasal probe and said force dissemination contact surface have a unitized construction.
10. An intranasal delivery device according to claim 1, further comprising a conformable dose sequestration element having a dose sequestration volume responsive to said flexible dose administrator.
11. An intranasal delivery device according to claim 10, wherein said conformable dose sequestration element further comprises a dose retainer, wherein said dose retainer has a location proximate to said stream delivery element.
12. An intranasal delivery device according to claim 11, wherein said dose retainer comprises a capillary.
13. An intranasal delivery device according to claim 12, wherein said capillary has a diameter of 3 millimeters (about 0.125 inches).
14. An intranasal delivery device according to claim 13, further comprising an axial collapse prevention element coupled to said flexible dose administrator.
15. An intranasal delivery device according to claim 14, wherein said axial collapse prevention element comprises a resiliently flexible layer between said cylindrical exterior surface of said flexible dose administrator and said conformable dose sequestration element.
16. An intranasal delivery device according to claim 15, wherein said resiliently flexible layer comprises polyvinyl chloride having a thickness of about 1.5 millimeters (0.040 inches).
17. An intranasal delivery device according to claim 16, further comprising a dose-location coordinate indicator coupled to said flexible dose administrator.
18. An intranasal delivery device according to claim 17, wherein said dose-location coordinate indicator comprises a visually enhanced surface.
19. An intranasal delivery device according to claim 18, wherein said visually enhanced surface comprises an annular projection.
20. An intranasal delivery device according to claim 19, wherein said dose-location coordinate indicator has a position which assures a dose-location coordinate temperature between about 26° C to about 34° C.
21. An intranasal delivery device according to claim 20, wherein said dose-location coordinate indicator has a position on said flexible intranasal probe distal from said stream delivery element of about 150 millimeters (about 5.9 inches).
22. An intranasal delivery device according to claim 21, further comprising a fluid dose propellant which separates said conformable dose sequestration element from said force application element.
23. An intranasal delivery device according to claim 22, wherein said flexible dose administrator and said dose sequestration element have a unitized construction.
24. An intranasal delivery device according to claim 23, further comprising an intranasal probe coupler having a first end responsive to said intranasal probe and a second end responsive to said flexible dose administrator, wherein said intranasal probe coupler provides a passage which communicates between said intranasal probe and said dose sequestration element.
25. An intranasal delivery device according to claim 24, wherein said intranasal probe coupler and intranasal probe comprise unitized construction.
26. An intranasal delivery device according to claim 25, wherein said intranasal probe coupler, said intranasal probe, and said force dissemination contact surface having hebetated termini comprise unitized construction.
27. An intranasal delivery device according to claim 26, wherein said first end of said force application element coupler comprises an annular barb engaged to said interior surface of said flexible dose administrator.
28. An intranasal delivery device according to claim 27, wherein said second end of said force application element coupler comprises a syringe adaptor.
29. An intranasal delivery device according to claim 28, wherein said syringe adaptor comprises a leur-lock.
30. An intranasal delivery device according to claim 29, wherein said force application element coupler and said dose-location coordinate indicator comprise unitized construction.
31. An intranasal delivery device according to claim 30, further comprising a dose responsive to said stream delivery element.
32. An intranasal delivery device according to claim 31, wherein said dose comprises a substance selected from the group consisting of a composition, a therapeutic composition, a prophylactic composition, a drug, a protein, a nucleic acid, an immunogen, an immunogen which elicits an immune response, a live virus, a reassortant live virus, a cold-adapted live virus, an attenuated live virus, an equine cold-adapted live influenza virus which replicates in embryonated chicken eggs within a temperature range from about 26°C to about 30°C, an equine influenza cold-adapted live virus which does not form plaques in tissue culture cells at a temperature above about 37°C, an equine influenza cold-adapted live virus which does not form plaques in tissue culture cells at a temperature above about 39°C, a equine cold-adapted live virus having a phenotype wherein protein synthesis is inhibited above about 39°C, an equine cold-adapted live virus having a dominant interference phenotype, an equine influenza cold-adapted live virus derived from strain A/equine/- Kentucky/1/91 (H3N8), EIV-P821(identified by accession No.
ATCC VR 2625), EIV-P824 (identified by accession No. ATCC VR 2624), MSV+5 (identified by accession No. 2627), any progeny of any of said equine influenza viruses identified by such accession Nos., any EIV having the identifying characteristics of said ATCC VR
strains, or an equine influenza cold adapted live virus having about 105 TCID50 to about 108 TCID50 units.
ATCC VR 2625), EIV-P824 (identified by accession No. ATCC VR 2624), MSV+5 (identified by accession No. 2627), any progeny of any of said equine influenza viruses identified by such accession Nos., any EIV having the identifying characteristics of said ATCC VR
strains, or an equine influenza cold adapted live virus having about 105 TCID50 to about 108 TCID50 units.
33. An intranasal delivery device according to claim 32, further comprising a volume of diluent, wherein said volume of diluent and said dose are combined.
34. Use of an intranasal delivery device according to any one of claims 1 to 33.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/408,584 | 1999-09-29 | ||
US09/408,584 US6398774B1 (en) | 1999-09-29 | 1999-09-29 | Intranasal delivery system |
CA002541848A CA2541848C (en) | 1999-09-29 | 2000-09-29 | Intranasal delivery system |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002541848A Division CA2541848C (en) | 1999-09-29 | 2000-09-29 | Intranasal delivery system |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2640663A1 true CA2640663A1 (en) | 2001-04-05 |
CA2640663C CA2640663C (en) | 2011-09-13 |
Family
ID=23616876
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2640663A Expired - Lifetime CA2640663C (en) | 1999-09-29 | 2000-09-29 | Intranasal delivery system |
CA002386110A Expired - Lifetime CA2386110C (en) | 1999-09-29 | 2000-09-29 | Intranasal delivery system |
CA002541848A Expired - Lifetime CA2541848C (en) | 1999-09-29 | 2000-09-29 | Intranasal delivery system |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002386110A Expired - Lifetime CA2386110C (en) | 1999-09-29 | 2000-09-29 | Intranasal delivery system |
CA002541848A Expired - Lifetime CA2541848C (en) | 1999-09-29 | 2000-09-29 | Intranasal delivery system |
Country Status (5)
Country | Link |
---|---|
US (2) | US6398774B1 (en) |
EP (1) | EP1225941A4 (en) |
AU (4) | AU774757B2 (en) |
CA (3) | CA2640663C (en) |
WO (1) | WO2001023018A2 (en) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6398774B1 (en) * | 1999-09-29 | 2002-06-04 | Heska Corporation | Intranasal delivery system |
US6651655B1 (en) * | 2000-01-18 | 2003-11-25 | Quadrant Technologies Limited | Inhaled vaccines |
US20040039352A1 (en) * | 2002-06-28 | 2004-02-26 | Paul Bergeson | Nasal dosing device |
NZ543196A (en) * | 2003-05-15 | 2008-04-30 | Univ Oklahoma State | DNA vaccine expressing HA1 but not HA2 of equine-2 influenza virus |
US7959929B2 (en) | 2005-04-21 | 2011-06-14 | University Of Florida Research Foundation, Inc. | Materials and methods for respiratory disease control in canines |
US11865172B2 (en) | 2005-04-21 | 2024-01-09 | University Of Florida Research Foundation, Inc. | Materials and methods for respiratory disease control in canines |
US8721699B2 (en) * | 2005-05-13 | 2014-05-13 | Benechill, Inc. | Methods and devices for non-invasive cerebral and systemic cooling |
US7824436B2 (en) * | 2005-05-13 | 2010-11-02 | Benechill, Inc. | Methods and devices for non-invasive cerebral and systemic cooling |
US9358150B2 (en) | 2005-05-13 | 2016-06-07 | Benechill, Inc. | Methods and devices for non-invasive cerebral and systemic cooling alternating liquid mist/gas for induction and gas for maintenance |
ES2496315T3 (en) | 2005-10-19 | 2014-09-18 | University Of Florida Research Foundation, Incorporated | Materials for the control of respiratory disease in canines |
WO2008005577A2 (en) * | 2006-07-07 | 2008-01-10 | University Of South Florida | Compositions of polyphenols and methods of use |
US7749191B2 (en) * | 2008-03-20 | 2010-07-06 | Beutlich Lp, Pharmaceuticals | Device and method for drug delivery |
US8015873B2 (en) * | 2008-04-25 | 2011-09-13 | Hall David L | Detector housing |
WO2010054249A1 (en) * | 2008-11-07 | 2010-05-14 | Benechill, Inc. | Methods of nasopharyngeal cooling for augmenting coronary perfusion pressure |
JP5908397B2 (en) | 2009-06-09 | 2016-04-26 | デフィルス、インコーポレイテッドDefyrus, Inc. | Interferon administration to prevent or treat pathogen infection |
WO2010144797A2 (en) | 2009-06-12 | 2010-12-16 | Vaccine Technologies, Incorporated | Influenza vaccines with enhanced immunogenicity and uses thereof |
WO2010148372A1 (en) | 2009-06-19 | 2010-12-23 | Benechill | Devices for cooling the nasal cavity |
WO2011156594A2 (en) | 2010-06-09 | 2011-12-15 | Vaccine Technologies, Incorporated | Therapeutic immunization in hiv infected subjects receiving stable antiretroviral treatment |
CA2835628C (en) | 2011-05-11 | 2023-01-03 | Children's Medical Center Corporation | Multiple antigen presenting immunogenic composition, and methods and uses thereof |
WO2014124228A1 (en) | 2013-02-07 | 2014-08-14 | Children's Medical Center Corporation | Protein antigens that provide protection against pneumococcal colonization and/or disease |
US11259908B2 (en) * | 2016-07-20 | 2022-03-01 | Elanco Us Inc. | Animal intranasal administration device, systems, and associated methods |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3950512A (en) | 1972-07-25 | 1976-04-13 | Pitman-Moore, Inc. | Animal vaccines |
US4009258A (en) | 1972-09-25 | 1977-02-22 | The Mount Sinai School Of Medicine Of The City University Of New York | Influenza vaccine containing a recombinant, antigenically hybridized virus and method of using the same |
US3927208A (en) | 1973-05-14 | 1975-12-16 | Rit Rech Ind Therapeut | Live bovine adenovirus vaccines, preparation thereof and method of vaccination using them |
US3953592A (en) | 1973-09-27 | 1976-04-27 | Recherche Et Industrie Therapeutiques (R.I.T.) | Live influenza virus vaccines and preparation thereof |
US4132775A (en) | 1973-12-03 | 1979-01-02 | Richardson-Merrell Inc. | Infectious bovine rhinotracheitis virus vaccine and method of preparing and using the same |
US4195076A (en) | 1974-03-05 | 1980-03-25 | Science Union Et Cie, Societe Francaise De Recherche Medicale | Process for the preparation of hemagglutinin from viral sources and methods of utilizing same |
FR2262962B1 (en) | 1974-03-05 | 1977-11-04 | Science Union & Cie | |
US4029763A (en) | 1974-08-05 | 1977-06-14 | Mount Sinai School Of Medicine Of The City University Of New York | Influenza vaccine containing purified neuraminidase antigen and method of using the same |
US3962422A (en) | 1975-02-18 | 1976-06-08 | Syntex (U.S.A.) Inc. | Method for immunizing nursing piglets against transmissible gastroenteritis(TGE) virus |
US4053583A (en) | 1976-03-01 | 1977-10-11 | Smithkline Corporation | Live newcastle disease virus vaccines |
US4110427A (en) | 1976-04-14 | 1978-08-29 | The Risdon Manufacturing Company | Powdered solid aerosol composition and method of manufacture |
US4110433A (en) | 1976-04-23 | 1978-08-29 | Philips Roxane, Inc. | Equine rhinopneumonitis virus |
US4512972A (en) | 1980-06-30 | 1985-04-23 | Kureha Chemical Industry Co., Ltd. | Nasal preparation and processes for their production |
US4554159A (en) | 1981-11-12 | 1985-11-19 | Institute Merieux | Vaccine and method of immunizing against herpes simplex virus (types 1 and 2) |
US4683137A (en) | 1982-04-16 | 1987-07-28 | Cornell Research Foundation, Inc. | Temperature sensitive reassortant viruses and a vaccine against equine influenza |
GB8300467D0 (en) | 1983-01-08 | 1983-02-09 | Wellcome Found | Equine influenza |
JPS59163313A (en) | 1983-03-09 | 1984-09-14 | Teijin Ltd | Peptide hormone composition for nasal administration |
US4554158A (en) | 1983-04-07 | 1985-11-19 | Simonsen Laboratories, Inc. | Modified live sendai virus vaccine for administering through an aerosol and method of producing the same |
US4962091A (en) | 1986-05-23 | 1990-10-09 | Syntex (U.S.A.) Inc. | Controlled release of macromolecular polypeptides |
US4767416A (en) * | 1986-12-01 | 1988-08-30 | Johnson & Johnson Patient Care, Inc. | Spray nozzle for syringe |
NZ224422A (en) | 1987-05-05 | 1990-11-27 | Molecular Eng Ass | Composition adapted for intranasal immunisation against viral infection comprising a glycoprotein complexed with a lipid |
US4800078A (en) | 1987-05-28 | 1989-01-24 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Immunotherapeutic method of treating respiratory disease by intranasal administration of Igb |
US5026825A (en) * | 1988-09-08 | 1991-06-25 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Intranasal calcitonin formulations |
US5250298A (en) | 1988-10-07 | 1993-10-05 | University Of Delaware | Live attenuated newcastle disease virus vaccines and preparation thereof |
US4923448A (en) * | 1988-12-06 | 1990-05-08 | Mark Anderson | Syringe with spray nozzle tip |
US5215739A (en) | 1989-04-05 | 1993-06-01 | Toko Yakuhin Kogyo Kabushiki Kaisha | Spray gel base and spray gel preparation using thereof |
US5158761A (en) | 1989-04-05 | 1992-10-27 | Toko Yakuhin Kogyo Kabushiki Kaisha | Spray gel base and spray gel preparation using thereof |
US5062423A (en) * | 1990-02-27 | 1991-11-05 | Minnesota Mining And Manufacturing Company | Equine aerosol drug delivery method and apparatus |
DE4016126A1 (en) * | 1990-04-17 | 1991-10-24 | Coster Tecnologie Speciali Spa | DEVICE FOR TRANSNASAL OR ORAL ADMINISTRATION OF MEDICATIONS OR THE LIKE |
US5053022A (en) * | 1990-06-28 | 1991-10-01 | Mobay Corporation | Applicator for intranasal administration of vaccines to horses |
IT1244803B (en) * | 1990-11-21 | 1994-09-05 | Promo Pack S A | SINGLE-DOSE DISPENSER-SPRAYER FOR ENDONASAL ADMINISTRATION OF LIQUID MEDICATIONS. |
US5331954A (en) * | 1990-12-21 | 1994-07-26 | Novo Nordisk A/S | Device for nasal delivery of liquid medications |
US5601077A (en) | 1991-08-07 | 1997-02-11 | Becton, Dickinson And Company | Nasal syringe sprayer with removable dose limiting structure |
US5429599A (en) * | 1994-05-02 | 1995-07-04 | Heinke; Richard M. | Method and means for delivering a pharmaceutical into the nostril of an animal |
DE19518810A1 (en) * | 1995-05-26 | 1996-11-28 | Bayer Ag | Nasal applicator |
US5683137A (en) | 1996-05-15 | 1997-11-04 | Bright Ideas Group, Inc. | Time-out chair/seat |
US5746762A (en) | 1996-06-24 | 1998-05-05 | Bass; Lawrence S. | Device and method for surgical flap dissection |
US6398774B1 (en) * | 1999-09-29 | 2002-06-04 | Heska Corporation | Intranasal delivery system |
US6382204B1 (en) * | 1999-10-14 | 2002-05-07 | Becton Dickinson And Company | Drug delivery system including holder and drug container |
-
1999
- 1999-09-29 US US09/408,584 patent/US6398774B1/en not_active Expired - Lifetime
-
2000
- 2000-09-29 CA CA2640663A patent/CA2640663C/en not_active Expired - Lifetime
- 2000-09-29 EP EP00967128A patent/EP1225941A4/en not_active Withdrawn
- 2000-09-29 US US10/089,224 patent/US7204822B1/en not_active Expired - Lifetime
- 2000-09-29 AU AU77376/00A patent/AU774757B2/en not_active Expired
- 2000-09-29 CA CA002386110A patent/CA2386110C/en not_active Expired - Lifetime
- 2000-09-29 CA CA002541848A patent/CA2541848C/en not_active Expired - Lifetime
- 2000-09-29 WO PCT/US2000/026870 patent/WO2001023018A2/en active IP Right Grant
-
2004
- 2004-10-07 AU AU2004218666A patent/AU2004218666B2/en not_active Expired
-
2006
- 2006-11-14 AU AU2006236004A patent/AU2006236004B2/en not_active Expired
-
2008
- 2008-06-06 AU AU2008202537A patent/AU2008202537A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU7737600A (en) | 2001-04-30 |
EP1225941A4 (en) | 2007-07-11 |
WO2001023018A3 (en) | 2001-12-06 |
EP1225941A2 (en) | 2002-07-31 |
US7204822B1 (en) | 2007-04-17 |
CA2541848A1 (en) | 2001-04-05 |
CA2541848C (en) | 2008-12-02 |
AU2008202537A1 (en) | 2008-06-26 |
AU774757B2 (en) | 2004-07-08 |
CA2386110A1 (en) | 2001-04-05 |
WO2001023018A2 (en) | 2001-04-05 |
AU2006236004A1 (en) | 2006-12-07 |
US6398774B1 (en) | 2002-06-04 |
AU2004218666B2 (en) | 2006-08-31 |
CA2640663C (en) | 2011-09-13 |
AU2004218666A1 (en) | 2004-11-04 |
AU2006236004B2 (en) | 2008-03-13 |
CA2386110C (en) | 2006-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2640663A1 (en) | Intranasal delivery system | |
Tumpey et al. | Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection | |
Clements et al. | Advantage of live attenuated cold-adapted influenza A virus over inactivated vaccine for A/Washington/80 (H3N2) wild-type virus infection | |
US7507411B2 (en) | Attenuated influenza NS1 variants | |
Stephenson et al. | Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers | |
Skoberne et al. | An adjuvanted herpes simplex virus 2 subunit vaccine elicits a T cell response in mice and is an effective therapeutic vaccine in Guinea pigs | |
AU760356B2 (en) | Cold-adapted equine influenza viruses | |
Baskin et al. | Functional genomic and serological analysis of the protective immune response resulting from vaccination of macaques with an NS1-truncated influenza virus | |
CA2223579C (en) | Novel recombinant temperature sensitive mutants of influenza | |
Baz et al. | Nonreplicating influenza A virus vaccines confer broad protection against lethal challenge | |
AU2006322907A1 (en) | Improved influenza vaccine | |
Gelb Jr et al. | Characterization of nephropathogenic infectious bronchitis virus DMV/1639/11 recovered from Delmarva broiler chickens in 2011 | |
Kim et al. | Complement C3 plays a key role in inducing humoral and cellular immune responses to influenza virus strain-specific hemagglutinin-based or cross-protective M2 extracellular domain-based vaccination | |
WO2013024113A1 (en) | Influenza h5 vaccines | |
EP3445398A1 (en) | Cold adapted and virulence factor deleted live attenuated vaccine suitable for mucosal delivery | |
Swayne et al. | Improvements to the hemagglutination inhibition test for serological assessment of recombinant fowlpox–H5-avian-influenza vaccination in chickens and its use along with an agar gel immunodiffusion test for differentiating infected from noninfected vaccinated animals | |
Ilobi et al. | Direct sequencing of the HA gene of clinical equine H3N8 influenza virus and comparison with laboratory derived viruses | |
CA2229430A1 (en) | Aqueous solvent based encapsulation of bovine herpes virus type-1 subunit vaccine | |
Deschambault et al. | Single immunization with recombinant ACAM2000 vaccinia viruses expressing the spike and the nucleocapsid proteins protects hamsters against SARS-CoV-2-caused clinical disease | |
JP2004290199A (en) | Non-splicing variants of gp350/220 | |
Kaverin et al. | Studies on the genetic basis of human influenza A virus adaptation to mice: degrees of virulence of reassortants with defined genetic content | |
Gruber | The role of live influenza vaccines in children | |
WO2014127825A1 (en) | H5 proteins of h5n1 influenza virus for use as a medicament | |
Besselaar et al. | Impact of the introduction of A/Sydney/5/97 H3N2 influenza virus into South Africa | |
Baz et al. | A single dose of an avian H3N8 influenza virus vaccine is highly immunogenic and efficacious against a recently emerged seal influenza virus in mice and ferrets |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |
Effective date: 20200929 |